These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 15056493)
1. Structure-activity relationships for the selectivity of hepatitis C virus NS3 protease inhibitors. Poliakov A; Johansson A; Akerblom E; Oscarsson K; Samuelsson B; Hallberg A; Danielson UH Biochim Biophys Acta; 2004 Apr; 1672(1):51-9. PubMed ID: 15056493 [TBL] [Abstract][Full Text] [Related]
2. Peptide-based inhibitors of the hepatitis C virus NS3 protease: structure-activity relationship at the C-terminal position. Rancourt J; Cameron DR; Gorys V; Lamarre D; Poirier M; Thibeault D; Llinàs-Brunet M J Med Chem; 2004 May; 47(10):2511-22. PubMed ID: 15115394 [TBL] [Abstract][Full Text] [Related]
3. Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-Length NS3 (protease-helicase/NTPase): a comparative study of different C-terminals. Johansson A; Poliakov A; Akerblom E; Wiklund K; Lindeberg G; Winiwarter S; Danielson UH; Samuelsson B; Hallberg A Bioorg Med Chem; 2003 Jun; 11(12):2551-68. PubMed ID: 12757723 [TBL] [Abstract][Full Text] [Related]
6. The effect of the P1 side chain on the binding of optimized carboxylate and activated carbonyl inhibitors of the hepatitis C virus NS3 protease. Kawai SH; LaPlante SR; Llinàs-Brunet M; Hucke O Future Med Chem; 2010 Jul; 2(7):1073-81. PubMed ID: 21426157 [TBL] [Abstract][Full Text] [Related]
7. Identification of non-macrocyclic small molecule inhibitors against the NS3/4A serine protease of hepatitis C virus through in silico screening. Chaudhuri R; Lee H; Truong L; Torres J; Patel K; Johnson ME J Chem Inf Model; 2012 Aug; 52(8):2245-56. PubMed ID: 22697413 [TBL] [Abstract][Full Text] [Related]
9. Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease. Llinàs-Brunet M; Bailey M; Déziel R; Fazal G; Gorys V; Goulet S; Halmos T; Maurice R; Poirier M; Poupart MA; Rancourt J; Thibeault D; Wernic D; Lamarre D Bioorg Med Chem Lett; 1998 Oct; 8(19):2719-24. PubMed ID: 9873610 [TBL] [Abstract][Full Text] [Related]
10. Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping. Landro JA; Raybuck SA; Luong YP; O'Malley ET; Harbeson SL; Morgenstern KA; Rao G; Livingston DJ Biochemistry; 1997 Aug; 36(31):9340-8. PubMed ID: 9235976 [TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships of HCV NS3 protease inhibitors evaluated on the drug-resistant variants A156T and D168V. Ortqvist P; Vema A; Ehrenberg AE; Dahl G; Rönn R; Akerblom E; Karlén A; Danielson UH; Sandström A Antivir Ther; 2010; 15(6):841-52. PubMed ID: 20834096 [TBL] [Abstract][Full Text] [Related]
12. Novel azapeptide inhibitors of hepatitis C virus serine protease. Bailey MD; Halmos T; Goudreau N; Lescop E; Llinàs-Brunet M J Med Chem; 2004 Jul; 47(15):3788-99. PubMed ID: 15239657 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of a diverse set of potential P1 carboxylic acid bioisosteres in hepatitis C virus NS3 protease inhibitors. Rönn R; Gossas T; Sabnis YA; Daoud H; Kerblom E; Danielson UH; Sandström A Bioorg Med Chem; 2007 Jun; 15(12):4057-68. PubMed ID: 17449253 [TBL] [Abstract][Full Text] [Related]
15. Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors. Llinàs-Brunet M; Bailey M; Fazal G; Ghiro E; Gorys V; Goulet S; Halmos T; Maurice R; Poirier M; Poupart MA; Rancourt J; Thibeault D; Wernic D; Lamarre D Bioorg Med Chem Lett; 2000 Oct; 10(20):2267-70. PubMed ID: 11055335 [TBL] [Abstract][Full Text] [Related]
16. Exploration of acyl sulfonamides as carboxylic acid replacements in protease inhibitors of the hepatitis C virus full-length NS3. Rönn R; Sabnis YA; Gossas T; Akerblom E; Danielson UH; Hallberg A; Johansson A Bioorg Med Chem; 2006 Jan; 14(2):544-59. PubMed ID: 16213143 [TBL] [Abstract][Full Text] [Related]
17. Novel hepatitis C virus protease inhibitors: thiazolidine derivatives. Sudo K; Matsumoto Y; Matsushima M; Fujiwara M; Konno K; Shimotohno K; Shigeta S; Yokota T Biochem Biophys Res Commun; 1997 Sep; 238(2):643-7. PubMed ID: 9299567 [TBL] [Abstract][Full Text] [Related]
18. HCV NS3 serine protease-neutralizing single-chain antibodies isolated by a novel genetic screen. Gal-Tanamy M; Zemel R; Berdichevsky Y; Bachmatov L; Tur-Kaspa R; Benhar I J Mol Biol; 2005 Apr; 347(5):991-1003. PubMed ID: 15784258 [TBL] [Abstract][Full Text] [Related]
19. Investigation of glycine alpha-ketoamide HCV NS3 protease inhibitors: effect of carboxylic acid isosteres. Han W; Jiang X; Hu Z; Wasserman ZR; Decicco CP Bioorg Med Chem Lett; 2005 Aug; 15(15):3487-90. PubMed ID: 15982872 [TBL] [Abstract][Full Text] [Related]
20. Phosphorous acid analogs of novel P2-P4 macrocycles as inhibitors of HCV-NS3 protease. Pompei M; Francesco ME; Koch U; Liverton NJ; Summa V Bioorg Med Chem Lett; 2009 May; 19(9):2574-8. PubMed ID: 19328685 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]